Immune Regulation News Volume 15.29 | Aug 4 2023

    By
    Laurisa Dohm
    -
    0
    67








    2023-08-04 | IRN 15.29


    Immune Regulation News by STEMCELL Technologies
    Vol. 15.29 – 4 August, 2023
    TOP STORY

    CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer

    The authors evaluated the activity of AMG 910, a CLDN18.2-targeted half-life extended bispecific T cell engager (BiTE) molecule in gastric cancer and pancreatic ductal adenocarcinoma preclinical models, and cocultured Tregs and effector T cells in the presence of CLDN18.2-HLE-BiTE.
    [Gastroenterology]

    AbstractFull Article
    Quantify Cytokines with Confidence with High-Performance ELISA Kits
    PUBLICATIONSRanked by the impact factor of the journal

    NF-κB Subunits Direct Kinetically Distinct Transcriptional Cascades in Antigen Receptor-Activated B Cells

    Scientists used time-dependent multi-omics to investigate the selective functions of Rel and RelA, two closely related NF-κB proteins, in primary B lymphocytes activated via the B cell receptor.
    [Nature Immunology]

    Full Article

    Donor T Cell STAT3 Deficiency Enables Tissue PD-L1–Dependent Prevention of Graft-Versus-Host Disease While Preserving Graft-Versus-Leukemia Activity

    Using murine models of graft-versus-host disease (GVHD), researchers showed that STAT3–/– donor T cells induced only mild reversible acute GVHD while preserving graft-versus-leukemia effects against nonsusceptible acute lymphoblastic leukemia cells in a donor T cell dose–dependent manner.
    [Journal Of Clinical Investigation]

    Full ArticleGraphical Abstract

    Tissue-Specific Features of the T Cell Repertoire after Allogeneic Hematopoietic Cell Transplantation in Human and Mouse

    Investigators examined the site-specificity of T cell receptor repertoires across tissues in prospectively collected autopsies of patients with and without graft-versus-host disease (GVHD), and in mouse models of GVHD.
    [Science Translational Medicine]

    Abstract

    A Bimetallic Nanoplatform for STING Activation and CRISPR/Cas Mediated Depletion of the Methionine Transporter in Cancer Cells Restores Anti-Tumor Immune Responses

    Scientists constructed a synergistic nanoplatform to promote CD8+ T cell infiltration in tumors while restoring T cell function by regulating methionine metabolism and activating the STING innate immune pathway.
    [Nature Communications]

    Full Article

    miR-15/16 Clusters Restrict Effector Treg Cell Differentiation and Function

    Mice with Treg-specific ablation of miR-15/16 clusters displayed attenuated immune responses during neuroinflammation and upon both infectious and non-infectious challenges.
    [Journal Of Experimental Medicine]

    Abstract

    The Splicing Isoform Foxp3Δ2 Differentially Regulates tTreg and pTreg Homeostasis

    AlphaFold2 predictions and in vitro experiments demonstrated that the N-terminal domain of Foxp3 inhibited DNA binding by moving toward the C terminus, and that this movement was mediated by exon 2.
    [Cell Reports]

    Full ArticleGraphical Abstract

    HIF-1 Regulates Pathogenic Cytotoxic T Cells in Lupus Skin Disease

    Using a mouse model of lupus skin disease, investigators found that skin-infiltrating CD4+ and CD8+ T cells also express high levels of hypoxia-inducible factor-1 (HIF-1).
    [JCI Insight]

    AbstractGraphical Abstract

    IL-33-Induced Neutrophilic Inflammation and NETosis Underlie Rhinovirus-Triggered Exacerbations of Asthma

    In mice with chronic experimental asthma, but not naïve controls, rhinovirus inoculation induced an early nflammatory response dominated by neutrophils, neutrophil-associated cytokines and NETosis, followed by a later, type-2 inflammatory phase.
    [Mucosal Immunology]

    Full ArticleGraphical Abstract
    Explore the Science Events Calendar to discover conferences, podcasts, webinars, and more!
    REVIEWS

    Eras of Designer Tregs: Harnessing Synthetic Biology for Immune Suppression

    The year 2022 marked the entry of “designer” Tregs into the clinic, with exciting potential for application and efficacy in a wide variety of immune-mediated diseases. The authors review the development of designer Tregs through the perspective of three ‘eras’ leading up to this.
    [Immunological Reviews]

    Full Article
    INDUSTRY AND POLICY NEWS

    NIH Selects Dr. Jeanne Marrazzo as Director of the National Institute of Allergy and Infectious Diseases

    Lawrence A. Tabak, D.D.S., Ph.D., acting director for the National Institutes of Health, has named Jeanne M. Marrazzo, M.D., as director of NIH’s National Institute of Allergy and Infectious Diseases.
    [National Institutes of Health]

    Press Release
    FEATURED EVENT

    Vaccinology during and after COVID-19

    September 17 – 19, 2023
    Atlanta, Georgia, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – Skin Inflammation & Regenerative Disease

    Institut Pasteur – Paris, France

    Assistant/Associate Professor – Immunology of Pancreatic Disorders

    Stanford University – Stanford, California, United States

    Postdoctoral Scientist – Tumor Immunology and Radio-Immunotherapy

    University of Alabama at Birmingham – Birmingham, Alabama, United States

    Faculty Positions – Advanced Immunochemical Studies

    ShanghaiTech University – Shanghai, China

    Postdoctoral Researcher – Rheumatoid Arthritis & Chronic Inflammatory Diseases

    Karolinska Institutet – Solna, Sweden

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Immune Regulation News Twitter